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Abstract 
Background: A recent interim analysis of the PRIME II placebo-controlled study showed a significantly higher mortality 
in the group treated with ibopamine than in the control group. The objective was to study mortality in patients on ibopamine, 
and to assess risk factors for death. 
Methods: All 2147 drug-dispensing outlets (DDO) in the Netherlands were asked to provide a printout of the complete 
medication history of users of ibopamine. A reaction was received from 92% of the DDO. From the 14 024 identified former 
or current users of ibopamine, a sample of 3148 patients (22%) was enrolled in the follow-up study. All general practitioners 
(GP) of these patients received an enquiry pertaining to the vital status of their patient, cause of death, primary cause and 
NYHA classification of heart failure, echo- and electrocardiographic data, serum creatinine, admissions and the effects of 
ibopamine. Cases were defined as patients who died during the follow-up period which ended on the day of return of the 
questionnaire or the day of decease (index date). Two random controls were obtained for each case from the non-deceased 
patients at the index date. The design was a follow-up study with risk factor assessment in a nested case-control design. 
Resuhs: Questionnaires were returned regarding almost 70% of the sample. Mortality in this group was 25%. A 
case-control analysis was performed with the first 104 cases and 208 random controls. Patients with NYHA class IV had a 
3-times increased risk of dying. In patients with a serum-creatinine level in the highest quartile the risk of dying was 
increased threefold. Higher doses of ibopamine seemed to have a protective ffect. Significantly more cases than controls 
used amiodarone. Also, opioids were used more often, which may be related to their use in terminal cardiac failure. 
Conclusion: NYHA classification and serum-creatinine levels were independent risk factors for death in patients with 
heart failure on ibopamine. Although there were increased risk estimates for current use of ibopamine and amiodarone, these 
did not reach statistical significance. This may be related, however, to the fact that this analysis was restricted to the first 
20% of cases. © 1997 Elsevier Science B.V. 
lCeywonts: Ibopamine; Case-control study; Amiodarone; Mortality; Pharmaco-epidemiology 
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1. Introduction 
Ibopamine is an oral dopamine agonist which was 
registered in the Netherlands in 1991 for the treat- 
ment of mild heart failure in combination with di- 
uretics, and for moderate to severe heart failure in 
combination with diuretics, angiotensin converting 
enzyme (ACE) inhibitors and/or digoxin. Ibopamine 
is rapidly converted into the active metabolite N- 
methyldopamine (epinine) by plasma and tissue es- 
terases. Epinine is excreted in the urine, after hepatic 
sulphate or glucuronic onjugation. In addition, epi- 
nine is metabolised by monoamine oxidase and cate- 
chol-o-methyltransferase and 75% is recovered in the 
urine as epinine metabolites. Epinine stimulates 
dopaminergic as well as [3-adrenergic receptors in 
the cardiovascular system. This results in vasodilata- 
tion in the renal, cardiac, cerebral and mesenteric 
vasculature. Ibopamine has a mild positive inotropic 
activity, decreases ympathetic activity, inhibits the 
renine-angiotensin-aldosterone syst m and has natri- 
uretic properties [1,2]. 
in 1992, in several European countries a random- 
ized placebo-controlled clinical trial (PRIME II) was 
started to study the effect of ibopamine on mortality 
in patients with moderate to severe heart failure. 
Patients were enrolled with New York Heart Associ- 
ation (NYHA) classification III, I I I / IV and IV. In an 
interim analysis in 1840 patients with an average 
follow-up of 18 months, the mortality in the group 
treated with ibopamine was significantly higher than 
in the control group. Based on these results, the 
indication for use of ibopamine was restricted in the 
Netherlands to mild forms of heart failure (NYHA 
class I / I I )  on 31st August, 1995 [3]. At the same 
time, the Inspectorate for Health Care started a study 
on the mortality in patients on ibopamine, and risk 
factors for death. 
2. Methods 
2.1. Setting 
On 1 September 1995, the Inspectorate for Health 
Care in the Netherlands i sued a warning regarding 
the restricted indication of ibopamine (Inopamil). An 
earlier study on the adverse effects to acitretin 
demonstrated that such warnings are well taken but 
that the large majority of medical practitioners are 
unable to ascertain to which patients they have pre- 
scribed a specific drug [4]. Especially, drugs pre- 
scribed by medical specialists are difficult to trace by 
their prescribers. Hence, on 6th September, the In- 
spectorate for Health Care sent a request to all 
drug-dispensing outlets (DDO) to make a computer 
printout of all current users of ibopamine and inform 
the prescribers, and to send an anonymized copy of a 
printout of all current users, and of those treated with 
ibopamine in the preceding year to the Inspectorate 
for Health Care. This request was sent to all 2147 
DDO in the Netherlands, comprising all 1516 com- 
munity pharmacies and 631 drug-dispensing general 
practitioners. The request was not sent to hospital 
pharmacies. A reminder was sent on 3 November 
1995. 
2.2. Source population 
A reaction was received from 1983 (92%) DDO, 
which had dispensed ibopamine to 14024 patients. 
The mean age of these patients was 75 years, of 
which 51.4% were male and 48.2% female patients. 
Corrected for non-response, the total number of pa- 
tients treated with ibopamine in the Netherlands in 
the preceding year was estimated at approximately 
15 000. In view of the total population in the Nether- 
lands of 15000000 inhabitants, the estimated 1- 
year-period population exposure prevalence was ap- 
proximately 0.1%. The average number of patients 
per community pharmacy was 8.9 (median:6; 
range:0-145), and per GP with a DDO 2.8 (median: 1; 
range:0-20). 
2.3. Study population 
All 1566 patients of general practitioners with a 
DDO, and a random sample of 1582 patients ob- 
tained through community pharmacies were enrolled 
in a follow-up study. All general practitioners of 
these patients received a questionnaire with ques- 
tions pertaining to the vital status of the patient, 
cause of death, primary cause of heart failure, New 
York Heart Association (NYHA) classification, echo- 
and electrocardiographic data, serum creatinine, ad- 
missions, and the effect of ibopamine on cardiac 
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status. Patients were followed from the first day of 
their first prescription in the medication history until 
the day of their death or the day of return of the 
questionnaire. 
2.4. Cases and controls 
Cases were patients who died during the follow-up 
period. The day of death of the case was defined as 
the index date. Two random controls were obtained 
for each case from the patients in the study popula- 
tion who were still alive on the index date. For the 
analysis of exposure status, the controls were as- 
signed the same index date as the case. 
2.5. Exposure status 
The use of ibopamine and all other drugs was 
obtained from the computer printouts. A drug-ex- 
posure window was defined as the period between 1 
month before the index date and the index date. 
Hereto, for every prescription the legend duration 
was calculated on the basis of the ratio of the total 
number of tablets or capsules and the prescribed 
daily number of tablets or capsules. A case or control 
was considered exposed to every drug for which the 
legend duration of the prescription overlapped the 
exposure window. 
2.6. Statistical analysis 
The risk of death according to various risk factors 
was estimated by calculation of odds ratios with a 
95% confidence interval [5]. Variables for which the 
distribution was significantly different between cases 
and controls in the univariate analysis, were included 
in a nmltivariate analysis according to an uncondi- 
tional logistic regression model. In the logistic re- 
gression analysis, the following variables were in- 
cluded in a forward stepwise fashion: NYHA classi- 
fication, serum creatinine level, angina pectoris, cur- 
rent use of ibopamine according to the general prac- 
titioner, use of digoxin, use of amiodarone and use 
of opioids. All analyses were done on a microcom- 
puter with SPSSPC (version 5.0.2) and EGRET as 
statistical packages. One-tailed chi-square trend anal- 
yses were performed with EpiInfo (version 5). 
3. Results 
Computerized prescription histories and question- 
naires have been obtained from almost 70% of the 
3148 patients. In this group, there were 493 deaths 
(25%). For logistic reasons, we had to restrict this 
analysis to the first 20% of cases. 
Hence, the study population in this report con- 
sisted of 104 cases and 208 controls. In Table 1, the 
general characteristics are given of cases and con- 
trols. Of the cases, 55% were male as against 45% of 
the controls. The average age of cases and controls 
was 77 and 76 years respectively. According to the 
general practitioners, almost 50% of patients died 
due to cardiac failure, 23% due to sudden cardiac 
death and 26% due to some other cause. 
Most patients were NYHA class IlI or IV. Pa- 
tients in the latter group had a 3-times increased risk 
of dying. The fact that the proportion of patients 
admitted to hospital was twice as high as in the 
group of controls was in accordance with the higher 
prevalence of NYHA class IV among the cases. 
Several cardiovascular diseases were similarly preva- 
lent in cases and controls (Table 1), with the excep- 
tion of angina pectoris which was more prevalent in 
cases. In cases, the average serum-creatinine l vel 
was significantly higher than in controls. In patients 
with a serum-creatinine l vel in the highest quartile 
(>  163 ixmol/1) the risk of dying was 3-times greater 
than in the lowest quartile. According to the data 
from the general practitioners' questionnaire, the im- 
provement of the cardiac status in controls was 
significantly higher than that in cases. Higher doses 
seemed to have a protective ffect, which could be 
compatible with a beneficial effect of ibopamine. 
According to the general practitioners, 54 of the 
cases (52%) were using ibopamine up to the moment 
of their death whereas 70 controls (34%) were still 
using ibopamine at the moment of the enquiry. Based 
on the computerized pharmacy data, however, 66% 
of cases and 57% of controls were still using 
ibopamine in the exposure window, 30 days before 
the index date. Of the 40 cases (39%) who stopped 
ibopamine, the cardiac condition remained stable in 
18 (45%), improved in 1 (2%), and worsened in 13 
(33%) patients (6 patients with NYHA class IV, 6 
patients with NYHA class III, and 1 with unknown 
cardiac status). In 8 patients (20%), the effect of 
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Table 1 
Characteristics of the study population 
Cases (n = 104) Controls (n = 208) Odds ratio/p-value 
Gender 
Females 47 (45%) 113 (55%) Reference 
Males 57 (55%) 93 (45%) 1.5 (0.9-2.4) 
Age (years) 77 (SE:0.9) 76 (SE:0.7) p = 0.25 
Cause of death 
Cardiac failure 49 (47%) 
Sudden death 24 (23%) 
Other 27 (26%) 
Unknown 4 (4%) 
NYHA Classification 
NYHA 1/11 6 (6%) 28 (14%) Reference 
NYHA III 45 (43%) 108 (52%) 1.9 (0.7-6.1) 
NYHA IV 43 (41%) 59 (28%) 3.4 (1 .2-10.9)  
Unknown 10 (10%) 13 (6%) - 
Chi-square trend: p = 0.004 
Coronary artery disease 62 (60%) 109 (52%) 1.3 (0.8-2.2) 
Hypertension 12 (12%) 28 (14%) (/.8 (0.4-1.8) 
Cardiomyopathy 36 (35%) 56 (27%) 1.4 (0.8-2.5) 
History of MI 61 (59%) 102 (49%) 1.5 (0.9 2.4) 
Angina pectoris 67 (64%) 106 (51%) 1.7 (1.1-2.9) 
Syncope < 5 years 32 (31%) 42 (20%) 1.8 (0.9-3.1) 
COPD 31 (30%) 60 (29%) 1.1 (0.6-1.8) 
Atrial fibrillation 44 (42%) 67 (32%) 1.5 (0.9-2.6) 
Diabetes mellitus 32 (31%) 59 (28%) 1.1 (0.7 1.9) 
S-Creatinine 163 (SE:I 1.7) 126 (SE:3.9) p = 0.0003 
< 96 txmol/I 15 (14%) 45 (22%) Reference 
96-1 i9 p.mol/l 17 (16%) 48 (23%) 1.1 (0.4-2.6) 
120 163 ~xmol/l 24 (23%) 40 (19%) 1.8 (0.8-4.2) 
> 163 ixmol/l 32 (31%) 31 (15%) 3.1 (1.4-7.2) 
Unknown 16 (15%) 44 (21%) 
Chi-square trend: p = 0.001 
Ibopamine improved cardiac status 39 (38%) 124 (60%) 0.4 (0.2-0.7) 
(< 2 months) 
Re-admitted because of cardiac failure 32 (31%) 38 (18%) 2.0 (t.1-3.6) 
Current use ibopamine ~' 
According to GP 54 (52%) 70 (34%) 2.1 (1.3-3.5) 
According to pharmacist 69 (66%) 119 (57%) 1.5 (0.9-2.5) 
Average duration of use (days) 220 (SE:25) 240 (SE: 16) p - 0.5 
Daily dose 
< 200 mg 24 (23%) 22 (l 1%) Reference 
201-400 mg 44 (42%) 129 (62%) 0.3 (0.2-0.7) 
>400mg 11(11%) 25(12%) 0.4 (0.1 1.1) 
Unknown 25 (24%) 32 (15%) - 
a Cases: still using ibopamine at time of death, controls: still using ibopamine at time of enquiry. 
Odds ratios and p-values ignificantly different from the null hypothesis are printed in bold. 
discontinuation was unknown. Of  the 99 controls 
(48%) who discontinued ibopamine, the cardiac con- 
dition remained stable in 73 (74%), improved in 9 
(9%) and worsened in 8 patients (8%). In 9 patients, 
the effect was unknown. 
In Table 2, the use of other drugs in the exposure 
window is given. Most  drugs were used by similar 
proportions of cases and controls. There were some 
exceptions as signif icantly more cases used the anti- 
arrhythmic agent amiodarone. Also, opioids were 
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Table 2 
Current use of drugs in cases and controls on index date 
167 
Drug ATC-code Cases(n = 104) Controls(n = 208) Odds ratio (95% CI) 
Insulins A10AA 9 25 0.7 (0.3-1.5) 
Biguanide hypogl. A10BA 5 8 1.3 (0.4-4.0) 
Sulfonylurea hypogl. A10BB 14 26 1.1 (0.5-2.2) 
Potassium salts A12BA 6 9 1.4 (0.5-3.9) 
Coumarines B01AA 36 68 1.1 (0.7-1.8) 
HMG-CoA reductase in. B04AB 1 9 0.2 (0.0-1.7) 
Digoxin C01AA 47 84 1.2 (0.8-2.0) 
Anti-arrhythmics (IA) C01BA 1 1 2.0 (0.1-32.5) 
Anti-arrhythmics (1C) C01BC 2 5 0.8 (0.2-4.2) 
Anti-arrhythmics (lid C01BD 12 11 2.3 (1.0-5.5) * 
Nitrates C01DA 36 85 0.8 (0.5-1.3) 
Thiazide diuretics C03AA 16 24 1.4 (0.7-2.9) 
Furosemides C03CA 85 155 1.5 (0.9-2.8) 
Aldosterone antagon. C03DA 14 30 0.9 (0.5-1.8) 
Other diuretics C03DB 10 17 1.2 (0.5-2.7) 
Vasodilators C04AX 2 2 2.0 (0.3-14.5) 
[3-Blockers C07AA 10 35 0.5 (0.2-1.2) 
Ca-antagonists I C08CA 8 13 1.3 (0.5-3.1) 
Ca-antagonists II C08DA 10 18 1.1 (0.5 2.5) 
ACE-inhibitors C09AA 61 110 1.3 (0.8-2.0) 
Corticosteroids H02AB 6 17 0.7 (0.3-1.8) 
NSAID M01AB 11 14 1.6 (0.7-4.0) 
Opioids N02AA 17 1 40.4 (5.3-308.7) *
Salicylates N02BA 23 56 0.8 (0.4-1.3) 
[3-Mimetic agents R03AB 10 13 1.6 (0.6-4.1) 
Corticosteroids inhal. R03BA 7 17 0.8 (0.3-2.0) 
Parasympathicolytics R03 BB 11 13 1.8 (0.8-4.1 )
Xanthine derivatives R03DA 3 6 1.0 (0.2-4.1) 
Statistically significant. 
used more often which is probably related to the use 
of these agents in the terminal phase of cardiac 
failure. 
In the logistic regression analysis, the fol lowing 
variables were included in a forward stepwise fash- 
ion: NYHA classification, serum creatinine level, 
angina pectoris, current use of  ibopamine according 
to the general practitioner, use of  digoxin, use of  
amiodarone and use of opioids. Although the latter is 
usually given in the final stage of the disease, it 
might contribute to death. Hence, it was included in 
the model. The multivariate analysis showed that 
NYHA classification with an odds ratio of 1.7 
(95%CI: 1.1-2.9) and serum-creatinine l vel with an 
odds ratio of  1.6 (95%CI: 1.2-2.2)  were independent 
risk factors for death but that a history of angina 
pectoris, current use of  ibopamine and amiodarone or 
digoxin were no longer significant. Re-analyses with 
current use of  ibopamine according to pharmacy 
data, dosage in 3 levels, and without opioids gave 
similar results. 
4. Discussion 
In this case-contro l  study nested in a cohort of  
ibopamine users, we found that NYHA classification 
and serum-creatinine l vels were independent risk 
factors for death in patients with heart failure. In 
view of the known pathophysiology of this disease, 
this is not surprising. The strong association between 
opioids and the risk of  death is a reflection of the use 
of these agents in the terminal phase of  the illness. In 
the univariate analysis, improvement of cardiac func- 
tion to ibopamine in the first 2 months of treatment 
was significantly less frequent in cases, according to 
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the general practitioner. Cases were significantly 
more frequently using ibopamine than controls on 
the index date. This may be explained in part by a 
liability of doctors to continue treatment in the more 
severe cases of heart failure (confounding by sever- 
ity). After correction for severity on the basis of 
NYHA classification, however, this association was 
still present, albeit no longer significant. It should be 
emphasized, however, that a significantly higher rate 
of exposure in cases was no longer present when the 
exposure status was based on the filling data from 
pharmacies. Fill ing data tend to be more reliable than 
prescription data from general practitioners. On the 
other hand, general practitioners might be better 
aware of any recent discontinuation of a drug shortly 
before a patients dies. Therefore, we performed the 
multivariate analysis twice with the 2 exposure defi- 
nitions but this had little effect on the results. Re- 
markably, the data are suggestive of a protective 
effect of higher doses of ibopamine or may be 
compatible with under-treatment i  cases by using a 
daily dose which is too low. The association with use 
of amiodarone in the univariate analysis is interest- 
ing as the PRIME II study suggests that the combina- 
tion of ibopamine and amiodarone may increase the 
risk of death. In our study, the association was no 
longer present in the multivariate analysis. The point 
estimate of the odds ratio of approximately 2, how- 
ever, persisted which is in line with the results from 
the PRIME II trial. 
There are some considerations which should be 
taken into account before drawing conclusions from 
our data. First, for logistic reasons we had to restrict 
this analysis to the first 104 cases. These came 
mostly from general practitioners with a drug-dis- 
pensing outlet, who have direct access to both drug 
dispensing and morbidity data and who have given 
excellent support o this kind of study in the past [6]. 
Although several of our findings are compatible with 
the results of the PRIME II study they may have 
been non-significant due to low numbers. Secondly, 
although we did distinguish between the different 
causes of death in our patients, overall mortality was 
used as the outcome despite the fact that sudden 
cardiac death or death by aggravating heart failure 
may have a different pathogenesis. Overall mortality 
was also the outcome in the PRIME II study, how- 
ever, and as it may be difficult to distinguish mortal- 
ity on the basis of data from general practitioners, we 
included all deaths in our analysis. Thirdly, our 
results are based on morbidity and mortality data 
from general practitioners. There is no reason to 
believe that general practitioners are not able to 
evaluate cardiovascular disease, and it is plausible 
that much of their data came from cardiologists. 
Even so, we were not able to check the consistency 
or validity of the data by reference to the original 
patient files, discharge summaries or medical records. 
In conclusion, the current study confirms that 
NYHA classification and serum-creatinine levels are 
independent risk factors for death in patients with 
heart failure who were treated with ibopamine. Al- 
though the use of opioids was strongly associated 
with death, this may be the result of their use in 
terminal patients rather than being a direct cause of 
death. Although current use of ibopamine and amio- 
darone were associated with an increased risk, these 
did not reach statistical significance in the multivari- 
ate analysis, possibly due to the fact that this case-  
control analysis was confined to the first 104 cases. 
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